Q1 Earnings Forecast for QuidelOrtho Issued By William Blair

QuidelOrtho Co. (NASDAQ:QDEL) – Stock analysts at William Blair lowered their Q1 2025 earnings per share (EPS) estimates for QuidelOrtho in a report issued on Wednesday, April 30th. William Blair analyst A. Brackmann now forecasts that the company will post earnings of $0.54 per share for the quarter, down from their prior estimate of $0.63. The consensus estimate for QuidelOrtho’s current full-year earnings is $2.30 per share. William Blair also issued estimates for QuidelOrtho’s FY2025 earnings at $2.18 EPS, Q1 2026 earnings at $0.62 EPS, Q2 2026 earnings at $0.38 EPS and FY2026 earnings at $2.89 EPS.

QuidelOrtho (NASDAQ:QDEL) last announced its earnings results on Wednesday, February 12th. The company reported $0.63 earnings per share for the quarter, missing the consensus estimate of $1.07 by ($0.44). QuidelOrtho had a negative net margin of 72.84% and a positive return on equity of 3.78%.

Several other brokerages have also recently issued reports on QDEL. Royal Bank of Canada lowered their price target on QuidelOrtho from $64.00 to $61.00 and set an “outperform” rating on the stock in a research report on Thursday, February 13th. JPMorgan Chase & Co. dropped their target price on shares of QuidelOrtho from $38.00 to $25.00 and set an “underweight” rating on the stock in a report on Monday, April 21st. UBS Group raised their target price on shares of QuidelOrtho from $43.00 to $45.00 and gave the stock a “neutral” rating in a report on Thursday, February 13th. Finally, StockNews.com cut QuidelOrtho from a “buy” rating to a “hold” rating in a report on Saturday, February 15th. One research analyst has rated the stock with a sell rating, four have issued a hold rating and three have given a buy rating to the company’s stock. According to MarketBeat, QuidelOrtho presently has an average rating of “Hold” and an average price target of $46.83.

QuidelOrtho Stock Up 4.4 %

QDEL stock opened at $29.12 on Friday. The firm’s 50-day moving average is $32.34 and its two-hundred day moving average is $38.48. The company has a current ratio of 1.22, a quick ratio of 0.69 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $1.96 billion, a price-to-earnings ratio of -0.96 and a beta of 0.43. QuidelOrtho has a 52 week low of $23.77 and a 52 week high of $49.45.

Institutional Trading of QuidelOrtho

A number of hedge funds have recently modified their holdings of QDEL. Segall Bryant & Hamill LLC raised its position in QuidelOrtho by 23.1% during the first quarter. Segall Bryant & Hamill LLC now owns 1,288,718 shares of the company’s stock valued at $45,066,000 after buying an additional 242,069 shares during the period. Victory Capital Management Inc. increased its holdings in shares of QuidelOrtho by 111.7% in the 1st quarter. Victory Capital Management Inc. now owns 67,528 shares of the company’s stock valued at $2,361,000 after purchasing an additional 35,631 shares during the period. CWM LLC lifted its position in shares of QuidelOrtho by 159.1% in the first quarter. CWM LLC now owns 87,966 shares of the company’s stock worth $3,076,000 after purchasing an additional 54,017 shares in the last quarter. New York State Common Retirement Fund boosted its holdings in shares of QuidelOrtho by 25.4% during the first quarter. New York State Common Retirement Fund now owns 42,845 shares of the company’s stock worth $1,498,000 after purchasing an additional 8,689 shares during the period. Finally, Cerity Partners LLC grew its position in QuidelOrtho by 222.4% during the first quarter. Cerity Partners LLC now owns 90,808 shares of the company’s stock valued at $3,176,000 after purchasing an additional 62,644 shares in the last quarter. Hedge funds and other institutional investors own 99.00% of the company’s stock.

QuidelOrtho Company Profile

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions.